HDAC11 inhibitor | HDAC11 Selective inhibitors | HDAC11 isoform specific inhibitor

製品コード	製品名	製品説明	Selective / Pan	IC50 / Ki
S6687	SIS17	SIS17 is a mammalian histone deacetylase 11 (HDAC 11)-specific inhibitor with IC50 of 0.83 μM. SIS17 inhibits the demyristoylation of HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.	Selective	HDAC11, IC50: 0.83 μM
S1096	Quisinostat (JNJ-26481585) 2HCl	Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.	Pan	HDAC11, IC50: 0.37 nM
S2759	Fimepinostat (CUDC-907)	CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.	Pan	HDAC11, IC50: 5.4 nM
S1515	Pracinostat (SB939)	Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. Pracinostat (SB939) induces apoptosis in tumor cells. Phase 2.	Pan	HDAC11, IC50: 93 nM
S1122	Mocetinostat (MGCD0103)	Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.	Pan	HDAC11, IC50: 0.59 μM
S7555	Domatinostat (4SC-202)	Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.	Pan	HDAC11, IC50: 9.7 μM

HDAC11 選択性 阻害剤

HDAC11 選択性阻害剤